|52Wk High:||52Wk Low:|
The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for best in class treatment of neurodegenerative diseases, in particular, Alzheimer's disease (AD) and ALS. ProMIS Neurosciences' proprietary target discovery engine is based on two, complementary techniques. The Company applies its thermodynamic, computational discovery platforms—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes on the surface of misfolded proteins. ProMIS has identified five target sites on toxic, misfolded strains of amyloid beta, a known root cause of Alzheimer's, and created five antibodies specific to these targets (without targeting amyloid beta monomer or plaque, known to be related to poor efficacy and side effects). Results of prior clinical trials indicate best in class AD therapy should target specifically toxic, misfolded strains of amyloid beta and not the other forms. ProMIS' AD program is uniquely designed and on track to achieve this goal. The Company's lead antibody product, PMN310 is in late preclinical development, with initiation of clinical trials expected in 2019.